PANC

Panacos Pharmaceuticals Inc

PANC, USA

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PANC
stock
PANC

Stevia leaf extract has potential as anticancer treatment, researchers find Medical Xpress

Read more →
PANC
stock
PANC

Management of pancreatitis in dogs and the role of PANOQUELL®-CA1 (fuzapladib sodium for injection) DVM360

Read more →

Showing 2 of 4

Finn Analysis

(Last Updated 2008-09-30)

Health Score

Return on Equity (ROE)

-

Very Low

-154.63 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.41 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-32,508.33 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

4.64

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Panacos Pharmaceuticals Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2008-09-30

EPS Actual

-0.15

EPS Estimate

-0.195

EPS Difference

0.045

Surprise Percent

23.0769%

Investing Fit Scorecard

(Last Updated 2008-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(3)
Net Net
Strong Net-Net(6.5)
Quality
Low Quality Business(1)
Value
Overpriced(1)

Income Statement

(Last Updated 2008-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2008-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2008-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.